Replies to post #189282 on Biotech Values

[jq1234]

If OCRX's oral version can low AL similar to IV in acute setting, it could compete against Ravicti in maintenance and chronic setting of HE as Ravicti didn't work well with patients who took Xifaxan based on ph2 trial:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237123/pdf/hep0059-1073.pdf

[DewDiligence]

HZNP acquires HPTX for $46/sh in cash—an 8% premium to Friday’s close:

http://finance.yahoo.com/news/horizon-pharma-plc-acquire-hyperion-100000624.html

The nominal deal value of $1.1B.

CC today at 8am ET.